Cancer immunotherapy .net
Information on human tumours 4
cancerimmunotherapy@yahoo.com
tumour type
Melanoma
Data in brief:

Intralesional interleukin-2 in metastatic malignant melanoma.

Intralesional IL-2 in metastases results in complete remissions in 2 patients.

85% of metastases have complete remission after intratumoral IL-2

Imiquimod plus IL-2 increases response rate compared to imiquimod as single therapeuticum in fase I/II study.
2007
Green et al. (2007) Br.J.Dermatol. 156, 337-45
2004
Phoehler et al. (2004) Hautartz 55, 171-5
2003
Br.J.Cancer 2003; 89, 1620-6
tumour type
Interleukin-2 (IL-2)
Mechanism of IL-2 therapy of cancer

Cancers sensitve to IL-2
Surgery and IL-2
Radiotherapy and IL-2
Chemotherapy and IL-2

Experts
I want to co-operate (doctors)
Frequently Asked Questions (FAQs)
Information for doctors

Information for patients

I want to support this research or  more information on the EPTI fund supporting this research
Our research is supported by Stichting ter bevordering van het onderzoek in de Experimentele Pathologie en in het bijzonder in de TumourImmunologie. Stichting EPTI, IJselstein, The Netherlands
1